Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIML NK cells + aldesleukin
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
CIML NK cells + aldesleukin is an investigational adoptive cellular immunotherapy regimen developed at the Washington University School of Medicine for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The approach involves the ex vivo activation of haploidentical donor-derived natural killer (NK) cells with a cytokine cocktail consisting of interleukin-12 (IL-12), IL-15, and IL-18 for 12-16 hours. This process induces a 'cytokine-induced memory-like' (CIML) phenotype, characterized by enhanced proliferation, longevity, and potent cytotoxic activity against myeloid leukemia cells. Following lymphodepleting chemotherapy, patients receive the CIML NK cell infusion followed by low-dose subcutaneous aldesleukin (recombinant IL-2) to support the expansion and persistence of the donor cells in the host environment.
- Other names
- Cytokine-induced memory-like NK cellsCIML NK cellsMemory-like NK cellsIL-2 supported CIML NK cell therapyIL2 supported CIML NK cell therapyIL 2 supported CIML NK cell therapy
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on CIML NK cells + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIML NK cells + aldesleukin.